Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that management will participate in one-on-one meetings with investors at the Morgan Stanley Private Company Biotech Corporate Access Day. The conference is being held in a virtual format on Tuesday, May 3rd, 2022.

About Tvardi Therapeutics

Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company’s lead product, TTI-101, is currently under investigation in a Phase 1 single agent multicenter clinical trial in patients with advanced solid tumors To date, TTI-101 has been well tolerated and demonstrated multiple durable radiographic objective responses in patients treated with TTI-101 monotherapy. To learn more, please visit https://tvarditherapeutics.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20220428006203/en/